These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 1027633)
1. Serum quinidine levels after chronic administration of four different quinidine formulations. Soeterboek AM; Van Thiel M; Eng C J Int Med Res; 1976; 4(6):393-401. PubMed ID: 1027633 [TBL] [Abstract][Full Text] [Related]
2. Comparison of quinidine plasma concentration curves following oral administration of some short- and long-acting formulations. Frigo GM; Perucca E; Teggia-Droghi M; Gatti G; Mussini A; Salerno J Br J Clin Pharmacol; 1977 Aug; 4(4):449-54. PubMed ID: 901736 [TBL] [Abstract][Full Text] [Related]
3. Bioequivalence of quinidine in two sustained-release preparations. Garty M; Rachmel A; Ilfeld D; Sinai Y; Paz R Isr J Med Sci; 1992 Jun; 28(6):357-61. PubMed ID: 1607272 [TBL] [Abstract][Full Text] [Related]
4. [Relative bioavailability and influence of a quinidine retard-formulation on blood-pressure and ECG in healthy volunteers (author's transl)]. Knapp W; Lechleitner P Arzneimittelforschung; 1981; 31(9):1482-6. PubMed ID: 7197960 [TBL] [Abstract][Full Text] [Related]
5. Enteric coated quinidine compared to sustained release preparations during repeated administration. Bakke OM; Aanderud L; Aslaksen A Acta Med Scand; 1980; 207(3):183-7. PubMed ID: 7368984 [TBL] [Abstract][Full Text] [Related]
7. Bioavailability of two manufacturers' sustained-release quinidine gluconate tablets at steady state. Zinny MA; Taggart WV Clin Ther; 1984; 7(1):22-7. PubMed ID: 6518461 [TBL] [Abstract][Full Text] [Related]
8. Bioavailability of quinidine in slow-release form. A comparison between two preparations containing quinidine bisulphate as the active constituent. RegÄrdh CG; Johnsson G; Lundborg P; Perrson BA Arzneimittelforschung; 1977; 27(9):1716-8. PubMed ID: 21671 [TBL] [Abstract][Full Text] [Related]
9. Disposition kinetics of two oral forms of quinidine. Mahon WA; Mayersohn M; Inaba T Clin Pharmacol Ther; 1976 May; 19(5 Pt 1):566-75. PubMed ID: 1277713 [TBL] [Abstract][Full Text] [Related]
10. [Relationship between quinidine plasma level and clinical effect for a new quinidine retard-formulation (author's transl)]. Gaul G; Aldor E Arzneimittelforschung; 1981; 31(9):1486-8. PubMed ID: 7197961 [TBL] [Abstract][Full Text] [Related]
11. Bioavailability of three commercial sustained-release tablets of quinidine in maintenance therapy. Huynh-Ngoc T; Chabot M; Sirois G J Pharm Sci; 1978 Oct; 67(10):1456-9. PubMed ID: 702302 [TBL] [Abstract][Full Text] [Related]
12. Comparative bioavailability study of three sustained release quinidine formulations. Mahon WA; Leeder JS; Brill-Edwards MM; Correia J; MacLeod SM Clin Pharmacokinet; 1987 Aug; 13(2):118-24. PubMed ID: 3621768 [TBL] [Abstract][Full Text] [Related]
14. Relative bioavailability of three commercial quinidine dosage forms. Sirois G; Eshaque M; Chabot M Biopharm Drug Dispos; 1980; 1(4):167-77. PubMed ID: 7448345 [TBL] [Abstract][Full Text] [Related]
15. Comparative quinidine plasma profiles at steady state of two controlled-release products and quinidine sulfate in solution. Wright GJ; Melikian AP; Pitts JE; Crowe JT; Morley EM Biopharm Drug Dispos; 1987; 8(2):159-72. PubMed ID: 3593896 [TBL] [Abstract][Full Text] [Related]